PortfoliosLab logo
RXRX vs. MSFT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RXRX and MSFT is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Performance

RXRX vs. MSFT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Microsoft Corporation (MSFT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

RXRX:

-0.56

MSFT:

0.39

Sortino Ratio

RXRX:

-0.60

MSFT:

0.70

Omega Ratio

RXRX:

0.93

MSFT:

1.09

Calmar Ratio

RXRX:

-0.61

MSFT:

0.39

Martin Ratio

RXRX:

-1.66

MSFT:

0.87

Ulcer Index

RXRX:

33.15%

MSFT:

10.69%

Daily Std Dev

RXRX:

93.11%

MSFT:

25.74%

Max Drawdown

RXRX:

-90.39%

MSFT:

-69.39%

Current Drawdown

RXRX:

-89.09%

MSFT:

-1.11%

Fundamentals

Market Cap

RXRX:

$1.85B

MSFT:

$3.38T

EPS

RXRX:

-$1.80

MSFT:

$12.95

PS Ratio

RXRX:

31.00

MSFT:

12.50

PB Ratio

RXRX:

1.98

MSFT:

10.49

Total Revenue (TTM)

RXRX:

$59.76M

MSFT:

$270.01B

Gross Profit (TTM)

RXRX:

-$46.00K

MSFT:

$186.51B

EBITDA (TTM)

RXRX:

-$534.16M

MSFT:

$150.06B

Returns By Period

In the year-to-date period, RXRX achieves a -33.28% return, which is significantly lower than MSFT's 9.28% return.


RXRX

YTD

-33.28%

1M

-18.00%

6M

-26.07%

1Y

-52.12%

3Y*

-5.88%

5Y*

N/A

10Y*

N/A

MSFT

YTD

9.28%

1M

25.00%

6M

11.02%

1Y

10.04%

3Y*

23.05%

5Y*

20.87%

10Y*

27.42%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Recursion Pharmaceuticals, Inc.

Microsoft Corporation

Risk-Adjusted Performance

RXRX vs. MSFT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX
The Risk-Adjusted Performance Rank of RXRX is 1515
Overall Rank
The Sharpe Ratio Rank of RXRX is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2020
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2222
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 1313
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 33
Martin Ratio Rank

MSFT
The Risk-Adjusted Performance Rank of MSFT is 6262
Overall Rank
The Sharpe Ratio Rank of MSFT is 6767
Sharpe Ratio Rank
The Sortino Ratio Rank of MSFT is 5757
Sortino Ratio Rank
The Omega Ratio Rank of MSFT is 5656
Omega Ratio Rank
The Calmar Ratio Rank of MSFT is 6868
Calmar Ratio Rank
The Martin Ratio Rank of MSFT is 6262
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RXRX vs. MSFT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Microsoft Corporation (MSFT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current RXRX Sharpe Ratio is -0.56, which is lower than the MSFT Sharpe Ratio of 0.39. The chart below compares the historical Sharpe Ratios of RXRX and MSFT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

RXRX vs. MSFT - Dividend Comparison

RXRX has not paid dividends to shareholders, while MSFT's dividend yield for the trailing twelve months is around 0.71%.


TTM20242023202220212020201920182017201620152014
RXRX
Recursion Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MSFT
Microsoft Corporation
0.71%0.73%0.74%1.06%0.68%0.94%1.20%1.69%1.86%2.37%2.33%2.48%

Drawdowns

RXRX vs. MSFT - Drawdown Comparison

The maximum RXRX drawdown since its inception was -90.39%, which is greater than MSFT's maximum drawdown of -69.39%. Use the drawdown chart below to compare losses from any high point for RXRX and MSFT. For additional features, visit the drawdowns tool.


Loading data...

Volatility

RXRX vs. MSFT - Volatility Comparison

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 27.16% compared to Microsoft Corporation (MSFT) at 8.73%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than MSFT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

RXRX vs. MSFT - Financials Comparison

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Microsoft Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B20212022202320242025
14.75M
70.07B
(RXRX) Total Revenue
(MSFT) Total Revenue
Values in USD except per share items